Ren T - Search Results

1

Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs.

Chen C, Xie L, Ren T, Huang Y, Xu J, Guo W. Chen C, et al. Among authors: ren t. Cancer Lett. 2021 Mar 1;500:1-10. doi: 10.1016/j.canlet.2020.12.024. Epub 2020 Dec 23. Cancer Lett. 2021. PMID: 33359211 Review.

2

Osteosarcoma cell intrinsic PD-L2 signals promote invasion and metastasis via the RhoA-ROCK-LIMK2 and autophagy pathways.

Ren T, Zheng B, Huang Y, Wang S, Bao X, Liu K, Guo W. Ren T, et al. Cell Death Dis. 2019 Mar 18;10(4):261. doi: 10.1038/s41419-019-1497-1. Cell Death Dis. 2019. PMID: 30886151 Free PMC article.

3

Knockdown of HMGA2 regulates the level of autophagy via interactions between MSI2 and Beclin1 to inhibit NF1-associated malignant peripheral nerve sheath tumour growth.

Yang K, Guo W, Ren T, Huang Y, Han Y, Zhang H, Zhang J. Yang K, et al. Among authors: ren t. J Exp Clin Cancer Res. 2019 May 3;38(1):185. doi: 10.1186/s13046-019-1183-2. J Exp Clin Cancer Res. 2019. PMID: 31053152 Free PMC article.

4

Macrophages reduce the sensitivity of osteosarcoma to neoadjuvant chemotherapy drugs by secreting Interleukin-1 beta.

Liang X, Guo W, Ren T, Huang Y, Sun K, Zhang H, Yu Y, Wang W, Niu J. Liang X, et al. Among authors: ren t. Cancer Lett. 2020 Jun 28;480:4-14. doi: 10.1016/j.canlet.2020.03.019. Epub 2020 Mar 24. Cancer Lett. 2020. PMID: 32220541

5

Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial.

Xie L, Xu J, Sun X, Guo W, Gu J, Liu K, Zheng B, Ren T, Huang Y, Tang X, Yan T, Yang R, Sun K, Shen D, Li Y. Xie L, et al. Among authors: ren t. J Immunother Cancer. 2020 May;8(1):e000798. doi: 10.1136/jitc-2020-000798. J Immunother Cancer. 2020. PMID: 32376724 Free PMC article. Clinical Trial.

6

miR-100-5p Inhibits Malignant Behavior of Chordoma Cells by Targeting IGF1R.

Zhang H, Yang K, Ren T, Huang Y, Liang X, Yu Y, Wang W, Niu J, Lou J, Tang X, Guo W. Zhang H, et al. Among authors: ren t. Cancer Manag Res. 2020 Jun 2;12:4129-4137. doi: 10.2147/CMAR.S252185. eCollection 2020. Cancer Manag Res. 2020. PMID: 32606920 Free PMC article.

7

Bone marrow mesenchymal stem cell-derived exosomal miR-206 inhibits osteosarcoma progression by targeting TRA2B.

Zhang H, Wang J, Ren T, Huang Y, Liang X, Yu Y, Wang W, Niu J, Guo W. Zhang H, et al. Among authors: ren t. Cancer Lett. 2020 Oct 10;490:54-65. doi: 10.1016/j.canlet.2020.07.008. Epub 2020 Jul 16. Cancer Lett. 2020. PMID: 32682951

8

Development of a prognostic gene signature based on an immunogenomic infiltration analysis of osteosarcoma.

Yu Y, Zhang H, Ren T, Huang Y, Liang X, Wang W, Niu J, Han Y, Guo W. Yu Y, et al. Among authors: ren t. J Cell Mol Med. 2020 Oct;24(19):11230-11242. doi: 10.1111/jcmm.15687. Epub 2020 Aug 21. J Cell Mol Med. 2020. PMID: 32820615 Free PMC article.

9

Identification of Potential Therapeutic Targets and Immune Cell Infiltration Characteristics in Osteosarcoma Using Bioinformatics Strategy.

Niu J, Yan T, Guo W, Wang W, Zhao Z, Ren T, Huang Y, Zhang H, Yu Y, Liang X. Niu J, et al. Among authors: ren t. Front Oncol. 2020 Aug 21;10:1628. doi: 10.3389/fonc.2020.01628. eCollection 2020. Front Oncol. 2020. PMID: 32974202 Free PMC article.

10

Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients.

Wang J, Zhang H, Sun X, Wang X, Ren T, Huang Y, Zhang R, Zheng B, Guo W. Wang J, et al. Among authors: ren t. J Nanobiotechnology. 2020 Oct 22;18(1):151. doi: 10.1186/s12951-020-00710-6. J Nanobiotechnology. 2020. PMID: 33092576 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,295 results

Search Page